Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Brilaroxazine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brilaroxazine hydrochloride overview
Brilaroxazine hydrochloride (RP-5063) is under development for the treatment of schizophrenia, schizoaffective disorder, idiopathic pulmonary fibrosis, behavioral and psychotic symptoms of dementia and Alzheimer’s disease (BPSD), major depressive disorder, pulmonary arterial hypertension, manic-depressive bipolar disorder, attention deficit/hyperactivity disorder, psychosis in Alzheimer’s disease and Parkinson’s diseases. RP-5063 is a new chemical entity and it is administered through oral and topical route in the form of gel. It targets dopamine D2, D3, D4, 5-HT1A, 5-HT2A, 5-HT2B,5HT2C, 5-HT6 and 5-HT7 receptors. The drug candidate is developed using chemical genomics based technology platform and proprietary chemistries.
It was also under development for Tourette syndrome and autism spectrum disorder.
Reviva Pharmaceuticals overview
Reviva Pharmaceuticals (Reviva Pharma) is a clinical development pharmaceutical company that develops therapeutic drugs. The company develops drugs in the therapeutic areas of cardiovascular, metabolic, central nervous system and inflammatory diseases. Its product pipeline comprises RP5063 for the treatment of schizophrenia disorders. Reviva Pharma’s product RP5063 is also been developing for Parkinson’s psychosis, attention deficit hyperactivity disorder, major depressive disorder, bipolar disorder, Alzheimer’s psychosis and agitation, and autism spectrum. The company also offers clinical trial services. Reviva Pharma is headquartered in Cupertino, California, the US.
For a complete picture of Brilaroxazine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
